Docetaxel, cyclophosphamide, and trastuzumab as neoadjuvant chemotherapy for HER2-positive primary breast cancer

被引：0
|
作者：
Katsuhiko Nakatsukasa
Hiroshi Koyama
Yoshimi Oouchi
Seiichi Imanishi
Naruhiko Mizuta
Kouichi Sakaguchi
Yoshifumi Fujita
Aya Imai
Akiko Okamoto
Asako Hamaoka
Mari Soushi
Ikuya Fujiwara
Tatsuya Kotani
Takayuki Matsuda
Kenichirou Fukuda
Midori Morita
Sadao Kawakami
Yayoi Kadotani
Eiichi Konishi
Akio Yanagisawa
Mariko Goto
Kei Yamada
Tetsuya Taguchi
机构：
[1] Kyoto Prefectural University of Medicine,Department of Endocrine and Breast Surgery
[2] Nara City Hospital,Department of Surgical Pathology
[3] Ayabe City Hospital,Department of Radiology
[4] Saiseikai Kyoto Hospital,undefined
[5] Saiseikai Shiga Hospital,undefined
[6] Fukuchiyama City Hospital,undefined
[7] Aiseikai Yamashina Hospital,undefined
[8] Kyoto Prefectural University of Medicine,undefined
[9] Kyoto Prefectural University of Medicine,undefined
来源：
Breast Cancer | 2017年 / 24卷
关键词：
Breast cancer; Human epidermal growth factor receptor 2-positive; Neoadjuvant chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：92 / 97
页数：5
相关论文
共 50 条
  • [1] Docetaxel, cyclophosphamide, and trastuzumab as neoadjuvant chemotherapy for HER2-positive primary breast cancer
    Nakatsukasa, Katsuhiko
    Koyama, Hiroshi
    Oouchi, Yoshimi
    Imanishi, Seiichi
    Mizuta, Naruhiko
    Sakaguchi, Kouichi
    Fujita, Yoshifumi
    Imai, Aya
    Okamoto, Akiko
    Hamaoka, Asako
    Soushi, Mari
    Fujiwara, Ikuya
    Kotani, Tatsuya
    Matsuda, Takayuki
    Fukuda, Kenichirou
    Morita, Midori
    Kawakami, Sadao
    Kadotani, Yayoi
    Konishi, Eiichi
    Yanagisawa, Akio
    Goto, Mariko
    Yamada, Kei
    Taguchi, Tetsuya
    [J]. BREAST CANCER, 2017, 24 (01) : 92 - 97
  • [2] Docetaxel, cyclophosphamide and trastuzumab as neoadjuvant chemotherapy in HER2-positive primary breast cancer.
    Nakatsukasa, Katsuhiko
    Taguchi, Tetsuya
    Sugimoto, Riho
    Sakaguchi, Kouichi
    Kotani, Tatsuya
    Hukuda, Kenichirou
    Kawakami, Sadao
    Hujiwara, Ikuya
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Cardiac safety of neoadjuvant chemotherapy with epirubicin and cyclophosphamide followed by docetaxel/pertuzumab/ trastuzumab for HER2-positive breast cancer patients
    Douganiotis, George
    Grigoriadis, Savvas
    Kontovinis, Loukas
    Markopoulou, Efrosini
    Pouptsis, Athanasios
    Papazisis, Konstantinos
    [J]. JOURNAL OF BUON, 2021, 26 (03): : 714 - 719
  • [4] Neoadjuvant chemotherapy with docetaxel, carboplatin and biosimilar trastuzumab in Her2-positive early breast cancer.
    Oukkal, Mohammed
    Challal, Souad
    Benmelha, Nawel Abed
    Benachenhou, Nabil
    Boubnider, Mohcen Wahib
    Kouchkar, Amal
    Terki, Nadia
    Benkhedda, Ghania
    Brahimi, Ghania
    Belkaid, Roza
    Bouzid, Kamel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer
    Isabel Echavarria
    Mónica Granja
    Coralia Bueno
    Sara Lopez-Tarruella
    Paloma Peinado
    Miguel Sotelo
    Yolanda Jerez
    Fernando Moreno
    Gabriela Torres
    Miriam Lobo
    Ivan Marquez-Rodas
    Maria Del Monte-Millan
    Miguel Martín
    Jose Angel García-Saenz
    [J]. Breast Cancer Research and Treatment, 2017, 162 : 181 - 189
  • [6] Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer
    Echavarria, Isabel
    Granja, Monica
    Bueno, Coralia
    Lopez-Tarruella, Sara
    Peinado, Paloma
    Sotelo, Miguel
    Jerez, Yolanda
    Moreno, Fernando
    Torres, Gabriela
    Lobo, Miriam
    Marquez-Rodas, Ivan
    Del Monte-Millan, Maria
    Martin, Miguel
    Angel Garcia-Saenz, Jose
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2017, 162 (01) : 181 - 189
  • [7] Neoadjuvant trastuzumab therapy with or without anthracycline containing chemotherapy for HER2-positive primary breast cancer
    Horiguchi, J.
    Koibuchi, Y.
    Rokutanda, N.
    Nagaoka, R.
    Sato, A.
    Odawara, H.
    Tokiniwa, H.
    Kikuchi, M.
    Lino, Y.
    Takeyoshi, I.
    [J]. EJC SUPPLEMENTS, 2010, 8 (03): : 73 - 73
  • [8] Effectiveness of Pertuzumab, Trastuzumab, and Docetaxel Combination Neoadjuvant Chemotherapy for HER2-Positive Inflammatory Breast Cancer: A Case Report
    Yamashita, Yuji
    Tanaka, Yuko
    Kono, Seishi
    Nishimura, Meiko
    Mukohara, Toru
    Morinaga, Yukiko
    Hara, Shigeo
    Takao, Shintaro
    [J]. BREAST CARE, 2017, 12 (01) : 45 - 47
  • [9] Complete response after "neoadjuvant" pertuzumab plus trastuzumab plus docetaxel chemotherapy in Her2-positive breast cancer
    Lai-Tiong, F.
    [J]. EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (05) : 836 - 837
  • [10] Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer
    Katsuhiko Nakatsukasa
    Hiroshi Koyama
    Yoshimi Oouchi
    Seiichi Imanishi
    Naruhiko Mizuta
    Kouichi Sakaguchi
    Yoshifumi Fujita
    Ikuya Fujiwara
    Tatsuya Kotani
    Takayuki Matsuda
    Kenichirou Fukuda
    Midori Morita
    Sadao Kawakami
    Yayoi Kadotani
    Eiichi Konishi
    Akio Yanagisawa
    Tetsuya Taguchi
    [J]. Breast Cancer, 2017, 24 : 63 - 68
12345